Impact Factor
4.61
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.73
9,990 total citations
h5-index
89
h5 depth signal
Cited share
87.2%
1,340 of 1,537
Total citations
9,990
Citation footprint
Metric signal
7.22
External metric anchor
Self-citation
3.5%
345 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
3,855
Germany
697
United Kingdom
664
Canada
602
France
602
Citing Fields of Research
Hematology
3,947
Lymphomas
1,687
Immunology
1,215
Oncology
364
Stem Cell Biology
219
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
6,328
Articles tracked across the journal lifetime
Indexed publication set
1,537
1,340 cited publications
Last 12 months
1,036
86.3 publications/month
Open access share
91.5%
948 OA publications in the last year
Leading citing country
United States
3,855 citing publications
Leading citing field
Hematology
3,947 citing publications
Latest tracked publication
27 October 2026
10 recent records available
Coverage & Indexing History
v1n4, Jan. 2017-
v1n1, 2016-
Active Coverage
Research Focus & Classification
Indexed Subjects
Hematology
Lymphomas
Issuing & Sponsoring Bodies
Array
American Society of Hematology
Broad Categories
Hematology
Lymphomas
MeSH Descriptors
Hematologic Diseases
Hematology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1182/bloodadvances.2026021567
Open DOI
A next-generation FVIIIa mimetic in the making
02
DOI 10.1182/bloodadvances.2026021833
Open DOI
Lineage plasticity: bridging development and leukemogenesis
03
DOI 10.1182/bloodadvances.2025018654
Open DOI
Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults
Precursor B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignant neoplasm. Relapsed or refractory (R/R) B-ALL carries a dismal prognosis. CD19-specific chimeric antigen receptor (CAR) T-cell therapy has emerge...
04
DOI 10.1182/bloodadvances.2026022111
Open DOI
Thromboprophylaxis and the treatment paradox in HA-VTE
05
DOI 10.1182/bloodadvances.2026020237
Open DOI
Anti-PF4 antibodies trigger a faster and stronger platelet procoagulant response than anti-heparin/PF4 antibodies
Vaccine-induced immune thrombocytopenia and thrombosis (VITT) and VITT-like syndromes are emerging causes of severe thrombocytopenia and thrombosis associated with immunoglobulin G (IgG) antibodies targeting platelet factor 4 (PF4). Thes...
06
DOI 10.1182/bloodadvances.2026021114
Open DOI
Patient-reported outcomes in clinical trials: lessons from the Blood and Marrow Transplant Clinical Trials Network
The Blood and Marrow Transplant Clinical Trials Network performs multicenter phase 2 and phase 3 clinical trials and has incorporated patient-reported outcome (PRO) measures into study protocols since its inception. As with clinical data...
07
DOI 10.1182/bloodadvances.2026020480
Open DOI
Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma
There is no established standard treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL). Zanubrutinib was approved in this setting based on the phase 2 MAGNOLIA trial. We retrospectively evaluated the characteristics and out...
08
DOI 10.1182/bloodadvances.2026020650
Open DOI
Boosting donor chimerism after sickle cell transplants
09
DOI 10.1182/bloodadvances.2026021166
Open DOI
A comprehensive review of T-cell lymphoma following CAR T-cell immunotherapy
Although chimeric antigen receptor (CAR) T-cell therapy provides a potential cure for patients with non-Hodgkin B-cell lymphomas/leukemias and plasma cell myelomas, rare reports of the development of T-cell lymphomas (TCLs) in these pati...
10
DOI 10.1182/bloodadvances.2025017997
Open DOI
CXCR4-dependent migratory differences between peripheral Tregs and Tcons preserve GVL while limiting GVHD after HSCT
Although studies on HLA-haploidentical hematopoietic stem cell transplant (HSCT) for high-risk acute myeloid leukemia (AML) showed that regulatory T-lymphocyte (Treg) and conventional T-lymphocyte (Tcon) immunotherapy prevents graft-vers...
Bibliographical & Catalog Notes
"Transforming the conversation".
Numbering from PDF article.
Only one issue published in Nov. 2016.
Also issued in print.